Search results for: Value-Based Pricing
Filter search results
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…markets. The analysis estimates a 19% fall in global revenues accounting for projected price rises outside of the US following the introduction of international reference pricing under H.R. 3 within…
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
1 April 2002
…concerned with total drug expenditures, which reflect volume and average prices for all products. Similarly, the pharmaceutical industry, in making decisions about pricing and launch of a drug in different…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…where the benefits are judged to be greater than the risks. Following regulatory approval, there are different national pricing and reimbursement processes, which in most cases, must conclude before patients…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
…returns from new drug development. Recently, the model has been used to evaluate the drug pricing provisions in the Build Back Better Act (BBBA). The CBO estimates that the policy…
Thomas Hamlyn
28 October 2025
…diseases, including his master’s dissertation which explored value-based pricing in rare diseases in the US and Germany using multi-criteria Decision analysis. Most recently he led strategic commercial analytics across the…
Exploring Local NHS Decisions about Investment
4 February 2011
…part of its programme of research relevant to NICE. The project is mentioned in the UK Government’s current consultation on value based pricing as generating results of direct relevance to…
Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?
1 October 2009
…cost benefit analysis to the payer perspective of cost-effectiveness analysis. Most voluntary and mandatory guidelines for evaluating medical innovation now encourage or require this narrower, budget-based payer perspective. As a…
OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
3 April 2013
…the market or the appearance of generics. Most projections of medicines spending are rooted in the past and are “top-down”, macro-based approaches. Such models are based on econometric analyses of…
Biosimilar Competition: Lessons from Europe and Prospects for the US
2 December 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US…